Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 58

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 1
Chunk 58
---
 Plan outstanding and exercisable at June 30, 2025:

			Number of RSU (#) 

			Exercisable at
			June 30, 2025 (#) 

			Expiry Date

			Fully-vested RSUs

			117,967

			117,967

			August 2033 - June 2035

			Vesting in the next 12 months

			262,090

			21,828

			May 2035

			Vesting from 13–24 months

			403,062

			22,364

			May 2035

			Vesting in 24 months or greater

			485,455

			14,087

			May 2035

			1,268,574

			176,246

			-

The Company has granted RSUs with varying vesting schedules. Certain RSU’s vest immediately upon the grant date, while others vest over a period ranging from 12 to 36 months. Outstanding RSUs can be converted to Common Shares by the holder at any time after vesting and before the expiry date. As of June 30, 2025, the Company had approximately $2.2 million of unrecognized restricted share unit compensation expense, which is expected to be recognized over a period of 35 months.

The Company recorded $0.2 million and $0.1 million of share-based compensation expenses for the three months ended June 30, 2025 and 2024, respectively and $0.3 million and $0.4 million for the nine months ended June 30, 2025 and 2024, respectively. These amounts include expenses related to both stock options and restricted share units (RSUs) granted to employees and directors under the Company’s equity compensation plans.

7. Government Contributions

Reimbursement grant income for the Company’s federal grant with the Canadian government’s SIF is recorded based on the claim period of eligible costs.

In October 2023, the Company entered into a multi-year contribution agreement (the 2023 SIF Agreement) with the Canadian Government’s Strategic Innovation Fund. Under the 2023 SIF Agreement, the Government of Canada committed up to C$23 million in partially repayable funding toward (i) conducting and completing the Company’s Phase 3 clinical study of its experimental drug EB05 in critical-care patients with Acute Respiratory Distress Syndrome (